Market Place
Sourcing Support
Nona Bio & Candid Therapeutics Collaborate on T-Cell Engagers
16 Dec 2024 //
PR NEWSWIRE
Nona Biosciences Partners With Alkyon for Immunotherapeutics Discovery
24 Sep 2024 //
PR NEWSWIRE
Nona Biosciences And Umoja Partner On In Vivo CAR-T Therapies
12 Sep 2024 //
PR NEWSWIRE
AstraZeneca and Nona Biosciences sign agreement for monoclonal antibody
23 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Nona Bio, AstraZeneca Partner On Tumor Targeted Antibody Therapy
22 May 2024 //
PR NEWSWIRE
Nona Biosciences Enters into Collaboration Agreement with Boostimmune
26 Feb 2024 //
PR NEWSWIRE
Pfizer picks up early-stage ADC candidate cleared for solid tumor trials
15 Dec 2023 //
ENDPTS
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033
14 Dec 2023 //
PR NEWSWIRE
Nona Announces Collaboration with Evive to Accelerate Antibody Discovery
10 Dec 2023 //
PR NEWSWIRE
Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics
04 Dec 2023 //
PR NEWSWIRE
Nona Biosciences Announces Strategic Collaboration with GeneQuantum
13 Nov 2023 //
PR NEWSWIRE
Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement
13 Oct 2023 //
PR NEWSWIRE
Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene
14 Sep 2023 //
PR NEWSWIRE
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart
28 May 2023 //
PR NEWSWIRE
Nona collaborates with PharmaEssentia for Nona’s Harbour mice platform
13 May 2023 //
PHARMABIZ
Nona Bio and Washington University join forces to tackle emerging RNA viruses
20 Apr 2023 //
PHARMABIZ
Harbour BioMed Announces IND Clearance for Anti-B7H7 Antibody by FDA
12 Jan 2023 //
PR NEWSWIRE
Harbour BioMed Establishes Wholly-Owned Subsidiary, Nona Biosciences
14 Nov 2022 //
CONTRACTPHARMA
Moderna picks up another antibody discovery deal via Harbour BioMed
11 Nov 2022 //
ENDPTS
Harbour BioMed completes first subject dosing in Phase I trial of HBM7008
21 Oct 2022 //
CLINICALTRIALSARENA
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB
20 Oct 2022 //
PRNEWSWIRE
Harbour Announces Presentations at Society for Immunotherapy of Cancer Meeting
13 Oct 2022 //
PRNEWSWIRE
Harbour Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP
27 Sep 2022 //
PRNEWSWIRE
Harbour BioMed Announces 2022 Interim Results
31 Aug 2022 //
PRNEWSWIRE
Harbour BioMed to Announce 2022 Interim Results on August 31, 2022
09 Aug 2022 //
PRNEWSWIRE
PNAS Published Preclinical Results of Harbour BioMed`s Ab Porustobart
08 Aug 2022 //
PRNEWSWIRE
Harbour BioMed concludes first patient dosing in Phase I antibody trial
26 May 2022 //
CLINICALTRIALSARENA
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB
25 May 2022 //
PRNEWSWIRE
Harbour BioMed to Present on Next-Gen Anti-CTLA-4 Ab HBM4003 at 2022 ASCO
10 May 2022 //
PRNEWSWIRE
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to Scientific Advisory Board
05 May 2022 //
PRNEWSWIRE
AstraZeneca bets $25M on pre-clinic bispecific versus hot target
08 Apr 2022 //
FIERCEBIOTECH
Harbour BioMed Signs Global Out-License Agreement with AZ for HBM7022
06 Apr 2022 //
PRNEWSWIRE
Harbour BioMed Reports Full Year 2021 Financial Results
24 Mar 2022 //
PRNEWSWIRE
Harbour BioMed Bags Approval for Phase I Trial of B7H4x4-1BB Bispecific Ab
28 Feb 2022 //
PRNEWSWIRE
Harbour BioMed Begins Dosing in Comb. Therapy Phase Ib/IIa of Anti-CTLA-4 Ab
24 Jan 2022 //
PRNEWSWIRE
Harbour BioMed Begins Dosing in Phase I Trials for HBM4003
04 Jan 2022 //
PRNEWSWIRE
Harbour BioMed Appoints Weihao Xu as Chief Strategy Officer
02 Dec 2021 //
HARBOURBIOMED
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial
19 Oct 2021 //
GLOBENEWSWIRE
Harbour BioMed begins dosing in phase II trial of anti-FcRn Ab, batoclimab
29 Sep 2021 //
PHARMABIZ
Harbour BioMed shows +ve results from PI trial of HBM4003 to treat solid tumors
14 Sep 2021 //
PHARMABIZ
NMPA approves Harbour BioMed`s PII trial of anti-FcRn Batoclimab in CIPD
02 Sep 2021 //
PHARMABIZ
Harbour BioMed Reports 2021 Interim Results
31 Aug 2021 //
PRNEWSWIRE
HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO
26 Jul 2021 //
PRNEWSWIRE
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab
07 Jul 2021 //
PR NEWSWIRE
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab
07 Jul 2021 //
PR NEWSWIRE
Harbour BioMed inks research pact with Dana-Farber Cancer Institute
16 Jun 2021 //
PHARMABIZ
Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/Iia
11 May 2021 //
PRNEWSWIRE
Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa
11 May 2021 //
PRNEWSWIRE
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021
14 Apr 2021 //
PRNESWIRE
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021
13 Apr 2021 //
PRNASA
Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study
22 Mar 2021 //
PRNEWSWIRE
Harbour BioMed Announces NMPA Approval of IND for Combination Therapy
25 Feb 2021 //
PRNEWSWIRE
Harbour BioMed`s Batoclimab (HBM9161) Receives China CDE Breakthrough
28 Jan 2021 //
PRNEWSWIRE
Harbour BioMed and Utrecht University Announce License Agreement with AbbVie
14 Dec 2020 //
PRNEWSWIRE
Harbour Will Present Results From Its PhII Trial with Tanfanercept (HBM9036)
16 Nov 2020 //
PRNEWSWIRE
Harbour BioMed Announces Dosing of 1ST Patients Two Ph II Studies of Batoclimab
30 Sep 2020 //
PRNEWSWIRE
Harbour BioMed Announces 2 China NMPA Approval for Clinical Trial of Anti-CTLA-4
21 Sep 2020 //
PRNEWSWIRE
Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology
24 Aug 2020 //
PRNEWSWIRE
More biotechs leverage upsized offerings in IPO boom as Harbour pitches a raise
20 Aug 2020 //
ENDPOINTSNEWS
AbbVie, Harbour BioMed, Utrecht University & Erasmus Announce Collaboration
04 Jun 2020 //
PRNEWSWIRE
